Page 24 - Complete Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study News provided by Share this article BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 /PRNewswire/ --  Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial (NCT04268706) in relapsed / refractory Classical Hodgkin Lymphoma (R/R cHL). The next step in the two-part study is enrollment of...

Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company's Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clinical Study (" Highlights from the Newsletter: Clinic...

To embed, copy and paste the code into your website or blog: An appellate court upheld a judgment that clever omissions from statements made by a corporate officer constituted securities fraud. On January 22, 2021, the U.S. Court of Appeals for the First Circuit in Boston, Massachusetts upheld a jury’s fraud verdict against an executive in a securities case tried in the U.S. District Court for the District of Massachusetts. 1  In a 30-page opinion, the Court in SEC v. Johnston 2  refused to overturn a verdict finding that defendant David Johnston, the former chief financial officer of AV...

Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (" UA") has received site Institutional Review Board (" IRB") approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clini...

Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology (" VU") has received site Institutional Review Board (" IRB") approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clinical Stud...